STOCK TITAN

Nektar Therapeutics - NKTR STOCK NEWS

Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.

Nektar Therapeutics (NKTR) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies for autoimmune disorders and chronic inflammatory diseases. This dedicated news hub provides investors and researchers with timely updates on the company's scientific advancements and corporate developments.

Access authoritative information on NKTR's pipeline progress, including updates on rezpegaldesleukin (Treg stimulator) and NKTR-255 (IL-15 agonist). Our curated collection features press releases about clinical trial milestones, regulatory submissions, strategic partnerships, and financial disclosures.

Key content categories include therapy development breakthroughs, FDA communications, research collaborations, and manufacturing updates. All materials are sourced directly from official company channels to ensure accuracy and compliance.

Bookmark this page for streamlined access to NKTR's latest developments in polymer conjugate chemistry and immunomodulation research. Check regularly for updates that could inform your understanding of the company's scientific trajectory and market position.

Rhea-AI Summary
Nektar Therapeutics (NKTR) to present at TD Cowen 44th Annual Health Care Conference in March 2024. Webcast accessible for replay until April 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
conferences
-
Rhea-AI Summary
Nektar Therapeutics (NKTR) is set to announce its Q4 and full-year 2023 financial results on March 4, 2024. The conference call hosted by President and CEO Howard Robin will provide insights into the company's performance. Investors can access the live webcast and replay through the Nektar website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.94%
Tags
-
Rhea-AI Summary
DiaMedica Therapeutics Inc. (DMAC) appoints Dr. Lorianne Masuoka, a board-certified neurologist with over 25 years of experience, as Chief Medical Officer. Dr. Masuoka has a successful track record in managing clinical programs and progressing the development of therapeutics for neurological disorders. The company granted her an inducement stock option to purchase 285,000 shares of DiaMedica's common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
management
Rhea-AI Summary
Nektar (NKTR) to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2024. Webcast accessible via Nektar website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Nektar Therapeutics (NASDAQ:NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College presented new preclinical data on NKTR-255 at the 65th American Society of Hematology (ASH) Annual Meeting. The data demonstrated that NKTR-255 significantly enhanced the cytotoxicity of expanded Natural Killer (NK) cells when combined with obinutuzumab against rituximab-resistant Burkitt Lymphoma (BL) cells and improved the survival of mice xenografted with Raji-4RH compared to controls. NKTR-255 is a novel polymer-conjugated human IL-15 receptor agonist currently being studied in three separate clinical studies in combination with cell therapies and immunotherapies. Preclinical and early clinical data suggest that NKTR-255 can improve proliferation and persistence of NK and CD8+ T cells to enhance specific anti-tumor activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
-
Rhea-AI Summary
Nasdaq: NKTR - Nektar Therapeutics Reports Q3 2023 Financial Results, Initiates Phase 2b Studies, and Announces Clinical Study Collaboration with Cellular Biomedicine Group
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
Rhea-AI Summary
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on November 7, 2023. The conference call to review the results will be hosted by Howard Robin, President and CEO, at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The press release and webcast can be accessed through the Nektar website. The webcast will be available for replay until December 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
-
Rhea-AI Summary
Nektar Therapeutics presents new data for REZPEG at the 2023 EADV Congress, demonstrating dose-dependent efficacy and sustained benefit for patients with atopic dermatitis. The therapy shows potential to alter the need for frequent maintenance dosing and opens the door for a new therapeutic class.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
-
Rhea-AI Summary
Nektar Therapeutics to present Phase 1b data for REZPEG and Phase 2b study design at EADV Congress. Highlights potential as a remittive therapy for atopic dermatitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none
Rhea-AI Summary
Nektar Therapeutics partners with Cellular Biomedicine Group Inc. for a clinical study on NKTR-255 and C-TIL051 combination therapy in NSCLC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
Nektar Therapeutics

Nasdaq:NKTR

NKTR Rankings

NKTR Stock Data

135.57M
183.75M
1.26%
71.87%
3.59%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO